-
2022Mass Spectrometry for Neurobiomarker Discovery: The Relevance of Post-Translational Modifications., Cells 2022 Apr; 11(8): .
-
2022Glycoproteogenomics characterizes the CD44 splicing code associated with bladder cancer invasion., Theranostics 2022 ; 12(7): 3150-3177.
-
2021Glycoproteomics identifies HOMER3 as a potentially targetable biomarker triggered by hypoxia and glucose deprivation in bladder cancer., J Exp Clin Cancer Res 2021 Jun; 40(1): 191.
-
2021Target Score-A Proteomics Data Selection Tool Applied to Esophageal Cancer Identifies GLUT1-Sialyl Tn Glycoforms as Biomarkers of Cancer Aggressiveness., Int J Mol Sci 2021 Feb; 22(4): .
-
2020Nucleolin-Sle A Glycoforms as E-Selectin Ligands and Potentially Targetable Biomarkers at the Cell Surface of Gastric Cancer Cells., Cancers (Basel) 2020 Apr; 12(4): .
-
2019Exploring sialyl-Tn expression in microfluidic-isolated circulating tumour cells: A novel biomarker and an analytical tool for precision oncology applications., N Biotechnol 2019 Mar; 49(): 77-87.
-
2019Protein Glycosylation and Tumor Microenvironment Alterations Driving Cancer Hallmarks., Front Oncol 2019 ; 9(): 380.
-
2018Glycan affinity magnetic nanoplatforms for urinary glycobiomarkers discovery in bladder cancer., Talanta 2018 Jul; 184(): 347-355.
-
2018Circulating tumor cells in bladder cancer: Emerging technologies and clinical implications foreseeing precision oncology., Urol Oncol 2018 May; 36(5): 221-236.
-
2018In silico approaches for unveiling novel glycobiomarkers in cancer., J Proteomics 2018 Jan; 171(): 95-106.
-
2018CD44 glycoprotein in cancer: a molecular conundrum hampering clinical applications., Clin Proteomics 2018 ; 15(): 22.
-
2017Sialyl-Tn identifies muscle-invasive bladder cancer basal and luminal subtypes facing decreased survival, being expressed by circulating tumor cells and metastases., Urol Oncol 2017 Dec; 35(12): 675.e1-675.e8.
-
2017Over forty years of bladder cancer glycobiology: Where do glycans stand facing precision oncology?, Oncotarget 2017 Oct; 8(53): 91734-91764.
-
2017Targeted O-glycoproteomics explored increased sialylation and identified MUC16 as a poor prognosis biomarker in advanced-stage bladder tumours., Mol Oncol 2017 Aug; 11(8): 895-912.
-
2016Moving toward personalized medicine in rheumatoid arthritis: SNPs in methotrexate intracellular pathways are associated with methotrexate therapeutic outcome., Pharmacogenomics 2016 Oct; 17(15): 1649-1674.
-
2016Hypoxia enhances the malignant nature of bladder cancer cells and concomitantly antagonizes protein O-glycosylation extension., Oncotarget 2016 Sep; 7(39): 63138-63157.
-
2015Smartphone application for rheumatoid arthritis self-management: cross-sectional study revealed the usefulness, willingness to use and patients’ needs., Rheumatol Int 2015 Oct; 35(10): 1675-85.
-
2015Emerging antibody-based therapeutic strategies for bladder cancer: A systematic review., J Control Release 2015 Sep; 214(): 40-61.
-
2015Pharmacogenomics of Methotrexate Membrane Transport Pathway: Can Clinical Response to Methotrexate in Rheumatoid Arthritis Be Predicted?, Int J Mol Sci 2015 Jun; 16(6): 13760-80.
-
2015Future perspectives of Smartphone applications for rheumatic diseases self-management., Rheumatol Int 2015 Mar; 35(3): 419-31.
-
2014SLC19A1, SLC46A1 and SLCO1B1 polymorphisms as predictors of methotrexate-related toxicity in Portuguese rheumatoid arthritis patients., Toxicol Sci 2014 Nov; 142(1): 196-209.
-
2014SLC19A1 80G allele as a biomarker of methotrexate-related gastrointestinal toxicity in Portuguese rheumatoid arthritis patients., Pharmacogenomics 2014 Apr; 15(6): 807-20.
-
2014Role of key TYMS polymorphisms on methotrexate therapeutic outcome in portuguese rheumatoid arthritis patients., PLoS One 2014 ; 9(10): e108165.
-
2014Prediction of methotrexate clinical response in Portuguese rheumatoid arthritis patients: implication of MTHFR rs1801133 and ATIC rs4673993 polymorphisms., Biomed Res Int 2014 ; 2014(): 368681.
-
2014Genetic polymorphisms in low-dose methotrexate transporters: current relevance as methotrexate therapeutic outcome biomarkers., Pharmacogenomics 2014 ; 15(12): 1611-35.
-
2013Current approaches for TYMS polymorphisms and their importance in molecular epidemiology and pharmacogenetics., Pharmacogenomics 2013 Aug; 14(11): 1337-51.